Biotech Innovations.

Citation metadata

Author: Jennifer Abbasi
Date: May 11, 2021
Publisher: American Medical Association
Document Type: Article
Length: 63 words

Document controls

Main content

Abstract :

A peptide vaccine designed to train the immune system to detect and eliminate micrometastic disease was proven safe in a phase 1 trial. Based on an assay that quantifies antibody levels in 30 minutes, researchers developed a SARS-CoV-2 test for use with whole blood from simple finger sticks or saliva samples. The EBOV D4 point-of-care antigen test could detect Ebola in decentralized facilities.

Source Citation

Source Citation   

Gale Document Number: GALE|A674192850